NCT02240667View on ClinicalTrials.gov

Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)

CompletedOBSERVATIONAL
Enrollment

1,506

Participants

Timeline

Start Date

September 18, 2014

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Atrial Fibrillation
Interventions
DRUG

Dabigatran etexilate

150 mg or 110 mg capsules twice daily

DRUG

Vitamin K antagonists

International Normalized Ratio (INR) 2-3

Trial Locations (1)

Unknown

Multiple Locations

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY